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Sulfadiazine and the metabolites N4-acetyl-sulfadiazine, 4-OH-sulfadiazine, 5-OH-sulfadiazine, 5-OH-glu- 
curonide-sulfadiazine, and 5-OH-sulfate-sulfadiazine were tested separately and in combination with py-
growth
pyrimethamine
concentration which in itself is not inhibitory, potentiated the microbial activity of sulfadiazine and its
metabolites 100 fold.
The combination of sulfadiazine and pyrimethamine is fre- by Derouin and Chastang (3). HEp-2 cells were prepared in
quently used for the treatment of Toxoplasma gondii infections 96-well tissue culture plates (Costar, Cambridge, Mass.) and
(9, 14). Both drugs act synergistically in the metabolic pathway grown to confluence. At the start of the assay, T. gondii para-
of folic acid, which in turn is required for the biosynthesis of sites of the RH strain were transferred to fresh culture medium
purines, pyrimidines and certain amino acids (4).
Studies on the antimicrobial activity of sulfadiazine metab­
olites are scarce. Pharmacokinetic studies of sulfadiazine so far 
have been performed by the method of Bratton and Marshall 
(1). This method, however, cannot discriminate between dif­
ferent hydroxylated metabolites of sulfadiazine. By using high- 
performance liquid chromatography (HPLC), a variety of hy­
droxy metabolites of sulfadiazine have been discovered in 
different animal species (11,12,19). Recently, HPLC determi­
nation of sulfadiazine in the plasma and the urine of rhesus 
monkeys revealed the presence of five metabolites of sulfadi­
azine: N4-acetyl-sulfadiazine (N4-acetyl), 4-OH-sulfadiazine 
(4-OH), 5-OH-sulfadiazine (5-OH), 5-OH-glucuronide-sulfa- 
diazine (5-OH-Gluc), and 5-OH-sulfate-sulfadiazine (5-OH- 
Sulf), (16a). It was thought previously that rhesus monkeys and 
humans were similar in their metabolization of sulfadiazine 
(10). However, the three 5-OH metabolites have not been 
found in humans.
A previous study with rhesus monkeys on the efficacy of 
pyrimethamine and sulfadiazine for the treatment of congen­
ital T. gondii infection (15) raised the question of whether the
of sulfadiazine possess antiparasitic activity. 
Nouws et al. (13) demonstrated that a hydroxylated metabolite 
of sulfadiazine had antimicrobial activity against Escherichia 
coli at 2.5% of the activity of the parental drug. N4-acetyl, on 
the other hand, showed no antimicrobial activity against this 
bacterium.
In the present study the anti-Toxoplasma activities of sulfa­
diazine and the metabolites that have been found in rhesus
at a concentration of 10s parasites per ml. Culture medium 
consisted of Dulbecco’s modified eagle’s medium (Gibco, 
Breda, The Netherlands) with 10 mM NaHC03 and 4.5 g of 
glucose per ml, supplemented with 3% fetal calf serum, 2 mM 
glutamine, 100 U of penicillin per ml, 0.5 mg of gentamicin per 
ml, 1 mM sodium pyruvate, and the desired concentrations of 
drugs to be studied. The HEp-2 cells were overlaid with 150 j j lI  
of a parasite suspension (parasite-to-cell ratio, 10/35). The 
parasites were grown at 5% C02, 90% humidity, and a tem­
perature of 36°C for 90 h. Each test included eight wells with­
out parasites (background staining of the HEp-2 cells) and 
eight wells with parasites but no drugs (positive control). Each 
drug concentration was tested eightfold, and each test was 
performed three times. The HEp-2 cells were stained with 
0.2% trypan blue and examined microscopically for their via­
bility.
After 90 h of incubation, the cultures were washed twice with 
wash buffer (136 mM NaCl, 27 mM KC1, 1.4 mM KH2P04, 8 
mM Na2HP04 • 2H20, 0.1% phenol red, and 0.05% Tween 
20), fixed with cold methanol, and air dried. The cells were 
incubated with a human antiserum against T. gondii at 37°C for 
2 h. The cells were subsequently incubated overnight at 4°C 
with a horseradish peroxidase-labeled rabbit anti-human im­
munoglobulin G, 1:10,000 (Dakopatts, Kopenhagen, Den­
mark). The substrate was 100 jxl of 4-mg/ml o-phenylenedia- 
mine (Sigma, St. Louis, Mo.) with 15-|jil/ml perhydrol 30% 
H20 2 (Merck, Darmstadt, Germany). The color reaction was 
terminated after a 5-min incubation at room temperature with 
100 ixl of 0.5 M H2S04. One hundred fifty microliters of the
monkeys were investigated in vitro. The activities of these substrate was then transferred to a 96-well plate for spectro-
drugs were also studied in combination with pyrimethamine. photometric analysis at 492 nm. Blank readings were per-
Anti-Toxoplasma activity was measured by quantitation of formed on the eight control wells without parasites. Py-
parasite growth using an enzyme-linked immunosorbent assay, rimethamine was obtained from the Wellcome Foundation
which was performed directly on T. gondii-'mftcted HEp-2 
cells. The in vitro tests were performed as described previously
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(Kent, England), sulfadiazine was obtained from the Onder­
linge Pharmaceutische Groothandel (Utrecht, The Nether­
lands), and N4-acetyl was obtained from Astra (Södertalje, 
Sweden). The metabolites of sulfadiazine, 4-OH, 5-OH, 5-OH- 
Gluc, and 5-OH-Sulf were isolated from rhesus monkey urine
by preparative HPLC (16a).
5-OH-Gluc and 5-OH-Sulf were dissolved in culture me-
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FIG, L Structural formulas of sulfadiazine and its metabolites N4-acetyl and hydroxy derivatives.
dium at a concentration of 10 and 2 mg/ml, respectively. Sul­
fadiazine and N4-acetyl were dissolved in culture medium at a 
concentration of 2 mg/ml by adjusting the pH to 8.4 with 1 M 
NaOH. When the drugs were completely dissolved, the pH was 
slowly reduced to 7.5 with 1 M HC1. 5-OH and 4-OH were 
dissolved in 100% AVV-dimethylformamide at a concentration 
of 10 mg/ml and subsequently diluted in culture medium. Py­
rimethamine was dissolved in methanol-acetone (50:50, vol/ 
vol) at a concentration of 0.1 mg/ml and further diluted in 
culture medium. Methanol and acetone had no inhibitory ef­
fect on Toxoplasma growth or toxic effect on the monolayer 
cells, at the concentrations that were used in the experiments. 
A/,N-dimethylformamide, alone or in combination with meth­
anol and acetone, also had no inhibitory or toxic effect at 
concentrations <1%. N,/V-dimethylformamide never reached 
concentrations of more than 0.5%.
Fifty percent inhibitory concentrations (IC50s) were deter­
mined for the sulfa compounds both alone and in combination 
with 0.05 jxg of pyrimethamine per ml. At this concentration 
pyrimethamine alone showed no inhibitory effect. Fifty percent 
inhibitory concentrations were determined by statistical anal­
ysis using a linear regression model as described by Derouin 
and Chastang (3). In brief, the optical densities (OD) obtained 
from the experiments were displayed as sigmoid curves when 
expressed as a function of the logarithms of the drug concen­
trations. The middle part of the sigmoid curve, showing the 
increase of inhibition, approximated a linear regression line. 
This line was adjusted to the basic OD measurements for three 
successive concentrations. Assuming a constant coefficient of 
variation, a weighted least-squares method was applied. The
mean OD measurements corresponding to a concentration of 
0 (noninhibitory concentration) and to a maximum inhibitory 
concentration (background) served as the limiting values. The 
IC5C) was obtained by inserting the OD value halfway between 
these limiting values in the equation of the adjusted regression 
line.
The structures of sulfadiazine and its metabolites which 
were investigated for their in vitro effects on T. gondii growth 
are shown in Fig. 1. IC50 could not be determined for the sulfa 
compounds separately, because the maximum concentrations 
of the drugs that could be dissolved had only a partial or
g ron paras
sulfadiazine and N4-acetyl were toxic for HEp-2 cells at con­
centrations higher than 1,000 (xg/ml. As a consequence, the 
concentration ranges that were tested did not result in a sig­
moid curve. The maximal concentrations that were tested are 
shown in Table 1.
IC50s were determined for sulfadiazine and its metabolites in 
combination with a constant concentration of 0.05 |xg of py­
rimethamine per ml. Except for N4-acetyl, the activities of 
sulfadiazine and its metabolites were enhanced in the presence 
of pyrimethamine. The concentrations of the sulfa compounds 
in combination with pyrimethamine were far below those of 
the drugs alone (Table 1). The IC50 of pyrimethamine alone 
was 0.2 ± 0.04 |xg/ml. The IC50s of pyrimethamine in combi­
nation with 25 and 100 |xg of the parental drug, sulfadiazine, 
were 0.02 ± 0.011 and 0.005 ± 0.003 |xg/ml, respectively. Con­
centrations of 25 and 100 fxg of sulfadiazine per ml are far 
below the inhibiting concentration of sulfadiazine alone (Table
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TABLE 1. Inhibitory effects of sulfadiazine and its metabolites 
alone and in combination with pyrimethamine on the growth of
T, gondii
ICS0 (|xg/ml)
Compound (g) Without
pyrimethamine*
With
pyrimethamine 
(0.05 |xg/ml)°
Sulfadiazine (250) > 1 ,000* 0.5 ±  0.25
N4-acetyl (292) > 1 ,000* > 1 ,000*
4-OH (267) >150c 0.6 ±  0.18
5-OH (267) >500e 0.5 ±  0.09
5-OH-Gluc (442) >2,500c 70 ±  0.32
5-OH-Sulf (346) >250^ 40 ±  0.34
a The data are means ± standard errors for three experiments. 
b IC50 not determined because the drug was toxic for HEp-2 cells at higher 
concentrations.
c IC50 not determined because the maximum solubility of the drug was 
reached.
d IC50 not determined because no more drugs were available.
1), but enhanced activity was found when these concentrations 
were tested in combination with pyrimethamine.
Metabolites of sulfadiazine which possess a freepara-amino- 
phenyl group are able to interfere in the folinic acid synthesis 
of T. gondii. The hydroxylated metabolites 4-OH and 5-OH 
have anti-Toxoplasma activities similar to that of the parental 
drug when used in combination with a concentration of py­
rimethamine that is by itself not inhibitory. The metabolites 
5-OH-Gluc and 5-OH-Sulf have lower anti-Toxoplasma activ­
ities. On the molar level, both components are 100 to 150 times 
less active than the parental drug. The extent of antimicrobial 
activity depends on the penetration of the metabolite into the 
parasitic cell, as has also been suggested for E. coli (13). 5-OH- 
Gluc and 5-OH-Sulf both dissolved very well in the culture 
medium. Conjugation of the OH group increases the hydro­
philic character of the metabolite and results in an enhanced 
excretion from the body in vivo. The hydrophilic character may 
cause poor penetration through the lipophilic parasitic mem­
brane. The N4-acetyl metabolite possesses no freepara-amino- 
phenyl group and is therefore unable to interact with the fo­
linic acid synthesis.
Sulfadiazine was found to inhibit T. gondii growth in vitro 
only at high concentrations. This finding is in agreement with 
those of other in vitro studies (7, 8, 16) but contrasts with the 
results of Derouin and Chastang (3). Since the assay we have 
used in this study is similar to the assay as described by Der­
ouin and Chastang (3), the discrepancy is difficult to explain. 
Genetic differences have been found between RH strains from 
different laboratories (6). A variation in sensitivity to antimi­
crobial agents between different Toxoplasma RH strains can­
not be excluded. Another explanation may be the 10-fold- 
higher concentration of parasites used in our study. When 
sulfadiazine or its metabolites were combined with py­
rimethamine, enhanced activity was found for all the combi­
nations tested, except for N4-acetyl. Again, the IC50s we have 
found were higher than those reported by Derouin and Chas­
tang (3). On the other hand, the results are in good agreement 
with the in vitro results reported by others, with regard to the 
parental drug (2, 5, 8). It is interesting that the IC50s we have 
found correspond to the plasma drug concentrations which are
effective in vivo (20).
This study shows that hydroxylated metabolites of sulfadia­
zine possess antimicrobial activity against T. gondii. The extent 
of hydroxylation depends on the type of species, age, and dose 
(11, 12, 17-19). The presence of antimicrobially active metab­
olites may have consequences for the efficacy of treatment 
when these metabolites are present in high concentrations or 
when effective concentrations in plasma are reached. There­
fore, extrapolation from animal studies to the human situation 
concerning the pharmacokinetics and efficacy of sulfadiazine 
should be done with care.
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